Tivic Health Systems has announced that enrolment in its pilot clinical study of a proprietary approach to non-invasive vagus nerve stimulation (VNS) has been completed.
Tivic is testing a proprietary approach to more precisely influence vagus nerve signals, while enhancing effectiveness and safety, with a non-invasive, bioelectronic treatment.
The pilot study utilised a new neurostimulation approach and involved 20 individuals, with the data collection and analysis being performed by researchers at the Feinstein Institutes for Medical Research in Manhasset, USA.
This work aims to provide more precise targeting strategies for VNS, and more control over the types of physiologic effects that result from stimulation, according to a Tivic press release.
“With study enrolment completed less than six months from initiation, we are looking forward to receiving and analysing the final study results,” said Jennifer Ernst, chief executive officer at Tivic. “This is one of the studies underway to expand Tivic’s non-invasive bioelectronic portfolio to new clinical uses beyond our existing product line.”
